Status:
COMPLETED
Magnesium, Vitamin B2, Feverfew, Andrographis Paniculata and Coenzyme Q10 for Episodic Migraine Prophylaxis
Lead Sponsor:
Corfu Headache Clinic
Conditions:
Migraine
Eligibility:
All Genders
Brief Summary
To investigate efficacy and safety of a supplementation with a fixed combination of magnesium, vitamin B2, feverfew, andrographis paniculata and coenzyme Q10 (Vivinor®) in episodic migraine prevention...
Detailed Description
To investigate efficacy and safety of a supplementation with a fixed combination of magnesium, vitamin B2, feverfew, andrographis paniculata and coenzyme Q10 (Vivinor®) in episodic migraine prevention...
Eligibility Criteria
Inclusion
- established diagnosis of episodic migraine with or without aura for more than one year prior to study entry
- evidence of 4-14 migraine days per month during the last trimester prior to screening
- participants may had been either treatment- naive or not suitable for or had failed previous migraine pharmacological prophylactic treatments
- were able to fully understand protocol and study information provided by the investigators.
- enrolled patients should take no other preventive treatment or use any other migraine prophylactic method during the three months before entering the study and throughout the study period.
Exclusion
- older than 50 years of age at migraine onset
- evidence of MOH
- pregnant or nursing females
- history of tension-type, cluster or hemiplegic headache
- history of severe anaphylactic reactions to any of the intervention's ingredients
- evidence of severe systemic diseases
- history or evidence of major psychiatric disorder.
Key Trial Info
Start Date :
April 1 2018
Trial Type :
OBSERVATIONAL
Allocation :
ACTUAL
End Date :
May 31 2020
Estimated Enrollment :
113 Patients enrolled
Trial Details
Trial ID
NCT04463875
Start Date
April 1 2018
End Date
May 31 2020
Last Update
July 9 2020
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Corfu HC
Corfu, Greece, 49100